1 friday, april 19 Biochemistry and Molecular Biology asbmb graduate and postdoctoral travel award keynote lecture special Session

P. Lu, R.A. Robinson, D.K. Meyerholz and J.D. 

Colgan. Univ. of Iowa. (53.4)

P96 

Use of the proximity ligation assay to detect immune 

complexes in histologic sections. 

K. Petrosky, K. 

Merriam and J.B. Rottman. Tufts Cummings Sch. of 

Vet. Med. and Amgen Inc., Cambridge, MA. 

(874.16)

P97 

Vibrio parahaemolyticus VopA is a potent inhibitor of cell 

growth and cell migration in the intestinal epithelium. 

R. Jones, L. Luo, G. Leoni and A. Nusrat. Emory 

Univ. Sch. of Med. 

(137.4)

P98 

Effects of dietary resistant starch on beta-catenin in 

azoxymethane-treated colonic epithelium. 

N. Cray, 

 

A. Pillatzki, Y. Zhao, D.F. Birt and E.M. Whitley. Iowa 

State Univ. 

(874.9)

P99 

Investigation of the utility of the simport-matrix 

chaperones for avian influenza virus sample 

storage and transportation. 

M. Echevarria, P. Ferro,  

C. Vuong, K. Metz, M. Hogan and B. Lupiani. Univ. of 

Puerto Rico at Ponce, Texas A&M Univ. and IntegenX 

Inc., Pleasanton, CA. 

(874.17)

P100  Remote lung injury after experimental intestinal 

ischemia-reperfusion in horses. 

J.B. Montgomery, S. 

Singh Suri, L. Johnson, D. Wilson and B. Singh. 

Univ. of Saskatchewan. 

(254.7)

P101 

Continuous exhaled breath carbon isotope analysis for 

early detection of sepsis. 

D.E. Butz, S.L. Morello, J. 

Sand, J.P. Boriosi, G.N. Holland and M.E. Cook. 

Sch. of Vet. Med. and Sch. of Med. and Publ. Hlth., 

Univ. of Wisconsin-Madison and Isomark LLC, 

Madison. 

(868.5)

P102  Chlorpyriphos induces lung inflammation and alters 

response to E. coli lipopolysaccharide challenge. 

A.A. 

Chougule, R. Sethi, D. Schneberger, R.S. Brar, 

J.P.S. Gill and B. Singh. Sch. of Animal Biotechnol. 

and Sch. of Publ. Hlth., Guru Angad Dev Vet. and 

Animal Sci. Univ., India and Univ. of Saskatchewan. 

(1166.17)

P103 

Sublethal hypoxic injury increases intestinal permeability 

via disruption of sealing tight junction proteins, but 

not pore forming tight junction proteins in human 

intestinal epithelium. 

Y. Jin and A.T. Blikslager. Col. 

of Vet. Med., North Carolina State Univ. 

(650.11)

Pharmacology and Experimental Therapeutics

394.  PHARMACOLOGY EDUCATION DIVISION: THE 

FUTURE OF PHD EDUCATION IN BIOMEDICINE: 

U.S. AND EUROPEAN PERSPECTIVES

Symposium

t

ue

. 9:30 

am

—W

estin

 B

oston

 W

aterFront

 h

otel

,  

G

ranD

 B

allroom

 e

C

haired

: J.a. m

itChell

Education

9:30 

PhD training in the USA: present and future. 

J. V. 

Barnett. Vanderbilt Univ. Med. Ctr.

10:00 

PhD education in the U.K.: why change? 

N. J. Goulding. 

Barts and The London Sch. of Med. and Dent.

10:30 

Standards of PhD education: the ORPHEUS perspective. 

M. J. Mulvany. Aarhus Univ. Grad. Sch. of Hlth. Sci., 

Denmark.

11:00 

Research funder perspective: PhD graduate attributes – 

future needs. 

C. A. Poudry. NIGMS, NIH.

11:30 

Roundtable discussion.

395.  ACETAMINOPHEN-INDUCED HEPATOTOXICITY: 

LESSONS LEARNED DURING THE LAST FOUR 

DECADES INVESTIGATING MECHANISMS OF 

TOXICITY

Symposium

(Sponsored by: The Divisions for Toxicology; Drug 

Discovery and Development; Drug Metabolism; and 

Pharmacology Education)

t

ue

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 106

C

haired

: J. m

anautou

 

anD

 h. J

aesChKe

9:30  Acetaminophen biotransformation and reactive 

intermediate toxicity: How did we get here? 

S. Cohen. 

Massachussetts Col. of Pharm. and Hlth. Sci.

10:05 

Mitochondria – oxidant stress and other signaling events 

associated with acetaminophen hepatotoxicity in mice 

and humans. 

H. Jaeschke. Univ. of Kansas Med. Ctr.

10:40  Role of vanin-1 in acetaminophen hepatotoxicity: 

regulation of thiol homeostasis and immune response 

to liver injury. 

J. E. Manautou. Univ. of Connecticut.

11:15  Acetaminophen plasma protein adducts: diagnostic 

markers and disease mechanisms in mice and 

humans. 

L. James. Univ. of Arkansas for Med. Sci.

11:50  Induction of neuronal nitric oxide synthase in livers of 

mice treated with toxic doses of acetaminophen. 

R. 

Agarwal, S. Banerjee and J.A. Hinson. Univ. of 

Arkansas for Med. Sci. 

(1106.8)

Visit The Exhibits

Sunday–Tuesday

9:00 AM–4:00 PM

TUESDAY PATHOLOGY/PHARMACOLOGY

112

396.  A “REDUCTIONIST” APPROACH TO 

CARDIOVASCULAR DISEASE: INORGANIC 

NITRATE TO NITRITE TO NO

Symposium

(Sponsored by: The British Pharmacological Society)

t

ue

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

C

haired

: a. a

hluWalia

 

anD

 D. l

eFer

9:30 

Inorganic nitrite – a metabolite with a mission! 

M. 

Gladwin. Vascular Med. Inst., Univ. of Pittsburgh.

10:05  Nitrite therapy in heart failure: mechanisms and 

therapeutic potential. 

D. Lefer. Emory Univ. Sch. of 

Med.

10:40 

The red blood cell nitrite reductase: a therapeutic target 

in hypertension. 

A. Ahluwalia. Queen Mary Univ. of 

London.

11:15  Dietary nitrate/nitrite and pulmonary hypertension. 

R. 

Baliga. Barts and The London Sch. of Med. and Dent.

11:50 Discussion.

397.  PURINERGIC TRANSMISSION IN VISCERAL 

FUNCTION AND SENSATION

Symposium

(Sponsored by: The Divisions for Integrative Systems, 

Translational and Clinical Pharmacology and Molecular 

Pharmacology)

t

ue

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107C

C

haired

: J. G

alliGan

 

anD

 h. a

KBarali

9:30 

Multiple purinegic neurotransmitters in the abdominal 

viscera. 

V. Mutafova-Yambolieva. Univ. of Nevada, 

Reno.

10:05 

Purinergic synaptic transmission in the enteric nervous 

system and control of gut motility. 

J. J. Galligan. 

Michigan State Univ.

10:40  Purinergic signaling in visceral pain mechanisms. 

C. 

Keating. Univ. of Sheffield.

11:15  Purinergic control of gastrointestinal secretion. 

F. 

Christofi. The Ohio State Univ.

11:50 Discussion.

398.  VOLTAGE-GATED ION CHANNEL BLOCKERS 

AS POTENTIAL ANALGESIC AGENTS

Symposium

(Sponsored by: The Divisions for Drug Discovery and 

Development and Neuropharmacology)

t

ue

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

C

haired

: m.F. J

arvis

9:30 

Structure and function of voltage-gated sodium channels 

at atomic level. 

W. A. Catterall. Univ. of Washington.

10:00  Chasing men on fire: sodium channels and pain. 

S. G. 

Waxman. Yale Univ. Sch. of Med.

10:30  Novel means of targeting T-type calcium channels to 

treat pain. 

G. W. Zamponi. Univ. of Calgary, Canada.

11:00 

Antinociceptive pharmacology of small molecule sodium 

channel blockers. 

M. F. Jarvis. AbbVie.

11:30 

Discovery and early clinical development of potent and 

selective small molecule Cav2.2 calcium channel 

blockers. 

S. Tate. Convergence Pharmaceut.

399.  TRANSCRIPTION FACTORS AS THERAPEUTIC 

DRUG TARGETS

Symposium

(Sponsored by: The Divisions for Molecular 

Pharmacology; Drug Discovery and Development; and 

Toxicology)

t

ue

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109a

C

haired

: t. F

iltz

 

anD

 m. l

eiD

9:30 

Regulating the regulators: transcription factor control by 

post-translational modification. 

M. Leid. Oregon State 

Univ. Col. of Pharm.

10:00  Activation of p53 tumor suppression by MDM2 

antagonists. 

L. T. Vassilev. Hoffmann-La Roche Inc.

10:30  Small molecule transcriptional modulators: structure 

and mechanism. 

A. Mapp. Univ. of Michigan.

11:00  Synthetic strategies for targeting protein-protein 

interactions. 

P. Arora. NYU.

11:30  Therapeutic applications of zinc finger nucleases. 

E. J. 

Rebar. Sangamo BioSciences Inc.

400.  CANADIAN SOCIETY OF PHARMACOLOGY 

AND THERAPEUTICS: PRACTICAL 

PHARMACOLOGY

Symposium

t

ue

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109B

C

haired

: r.B. K

im

Interesting cases from Clinical Pharmacology consults 

or clinics will be outlined in an interactive fashion to highlight 

mechanisms of drug action, drug-drug interactions, and 

application of pharmacogenomics to patient care.

401.  CANADIAN SOCIETY OF PHARMACOLOGY 

AND THERAPEUTICS: WOMEN AND 

PREGNANCY: SAFETY, EFFICACY, ETHICS AND 

RESEARCH NEEDS IN PHARMACOLOGY

Symposium

t

ue

. 1:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109B

C

haired

: D. K

noppert

1:00 

Opening remarks. 

D. Knoppert. Children’s Hlth. Res. 

Inst., London, ON.

1:15  Pharmacokinetics and gender differences. 

D. R. 

Mattison. Risk Sci. Intl.

2:00 

Impact of Pregnancy on maternal pharmacokinetics of 

medications. 

M. F. Hébert. Univ. of Washington.

2:30 

Pharmacokinetics and Bioequivalence — evaluating the 

risks. 

G. Koren. Univ. of Toronto.

3:00 Break.

3:15 

Gender barriers in policy and regulation. 

M. Nolan. Soc. 

for Women's Hlth. Res.

PHARMACOLOGY TUESDAY

113

T

U

E

3:45 

Removing risks to prescribing in pregnancy: next steps 

in research and regulation. Panel discussion. 

D. R. 

Mattison. Risk Sci. Intl.

4:45 

Closing remarks. 

D. Knoppert. Children’s Hlth. Res. 

Inst., London, ON.

402.  CARDIOVASCULAR PHARMACOLOGY 

DIVISION TRAINEE SHOWCASE

Oral

t

ue

. 2:30 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

C

haired

: J.p. m

uraD

 

anD

 s. s

onKusare

2:30 

Sestrin2 is cardioprotective against ischemia/reperfusion 

injury by promoting LKB1-mediated AMPK activation. 

A. Morrison-Nozik, C. Tong, J.H. Lee, A. Budanov, 

M. Karin and J. Li. Univ. at Buffalo, SUNY, Univ. of 

Michigan, Virginia Commonwealth Univ. and UCSD. 

(652.9)

2:45 

Pregnane X receptor mediates dyslipidemia induced by 

the HIV protease inhibitor amprenavir in mice. 

R.N. 

Helsley, Y. Sui, N. Ai, S-H. Park, W.J. Welsh and C. 

Zhou. Univ. of Kentucky and UMDNJ, Piscataway. 

(1169.20)

3:00 

Heterogeneity of ATP-sensitive K

+

 channels in cardiac 

myocytes: enrichment at the intercalated disk. 

M. 

Hong, L. Bao, E. Kefaloyianni, E. Agullo-Pascual, 

H. Chkourko, M. Foster, E. Taskin, D.A. Reid, E. 

Rothenberg, M. Delmar and W.A. Coetzee. NYU 

Sch. of Med. 

(879.7)

3:15 

Genetic deletion of the TRPC3 channel blunts the 

development of angiotensin II-induced hypertension 

in mice. 

A.R. Pathan, B. Fields, L. Birnbaumer, 

F. Zheng and N.J. Rusch. Univ. of Arkansas for 

Med. Sci. and NIEHS, NIH, Research Triangle Park. 

(654.18)

3:30 

Angiotensin II receptor blockade, but not ACE inhibition, 

reduces nocturnal hypertesion and natriuresis in 

autonomic failure patients with low renin activity. 

A.C. 

Arnold, L.E. Okamoto, A. Gamboa, C.A. Shibao, 

S.R. Raj, D. Robertson and I. Biaggioni. Vanderbilt 

Univ. 

(654.19)

3:45 

Aged eNOS-/- mice display increased APP expression, 

microglial activation, and impaired spatial memory. 

S.A. Austin, A.V. Santhanam, D.J. Hinton, D-S. 

Choi and Z.S. Katusic. Mayo Clin. (1177.3)

403.  BENEDICT R. LUCCHESI DISTINGUISHED 

LECTURE IN CARDIAC PHARMACOLOGY

Lecture

t

ue

. 4:30 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

The Benedict R. Lucchesi Award in Cardiac Pharmacology 

was established by ASPET’s Division for Cardiovascular 

Pharmacology to honor Dr. Lucchesi’s lifelong scientific 

contributions to our better understanding and appreciation of 

the pharmacological treatment and prevention of cardiovascular 

disease and for his mentoring of countless prominent 

cardiovascular pharmacologists in translational approaches. 

Dr. Andre Terzic was selected in recognition of his landmark 

contributions in our understanding of cardioprotective and 

cardioregenerative strategies. His scientific success is matched 

by his outstanding mentorship and dedication to the scientific and 

medical community.

4:30 Introduction. 

N. Rusch. Univ. of Arkansas for Med. Sci.

4:35 

Regenerative cardiac pharmacology: the next frontier. 

A. 

Terzic. Mayo Clin.

404.  NEGATIVE SYMPTOMS OF SCHIZOPHRENIA: 

NEURONAL CIRCUIT, TRANSLATION AND 

FUTURE DIRECTIONS

Symposium

(Sponsored by: The Divisions for Drug Discovery 

and Development; Behavioral Pharmacology; and 

Neuropharmacology)

t

ue

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 106

C

haired

: r. G

aliCi

 

anD

 l. J

aCoBsen

3:00 

Negative symptoms: clinical features and prospects for 

treatment. 

B. Kirkpatrick. Scott & White Healthcare.

3:35 

Emotion and motivation deficits in schizophrenia: 

the behavioral and neural substrates of negative 

symptoms. 

A. M. Kring. Univ. of California, Berkeley.

4:10 

Modeling negative symptoms of schizophrenia in 

animals. 

A. Markou. UCSD.

4:45  Pharmacotherapies for negative symptoms of 

schizophrenia. 

L. Jacobsen. Bristol-Myers Squibb.

5:20 Discussion.

405.  INTEGRATIVE SYSTEMS, TRANSLATIONAL 

AND CLINICAL PHARMACOLOGY DIVISION 

HOT TOPICS: A (R)EVOLUTION IN DRUG 

DISCOVERY & THERAPY: FROM ORGANS ON A 

CHIP AND 3D BIOMIMETICS TO REGENERATIVE 

PHARMACOLOGY

Symposium

t

ue

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107C

C

haired

: G.J. C

hrist

 

anD

 s. s

ittamplam

3:00 

Chair’s introduction.

3:10 

Human organs-on-chips. 

D. Ingber. Harvard Med. Sch.

3:45  Rapid fabrication of architecturally-correct human 

tissues in vitro by 3D bioprinting: function follows form. 

S. Presnell. Organovo Inc., San Diego.

4:20 

Silk: a multifunctional biomaterial with applications for 

controlled drug delivery, tissue repair and engineering 

3D tissues. 

D. Kaplan. Tufts Univ. 

4:55 

Microscale engineering of tissues and organs. 

L. 

Griffith. MIT

TUESDAY PHARMACOLOGY

114

406.  TOXICOLOGY DIVISION: THE MITOCHONDRION  

AS A TOXICOLOGICAL AND 

PHARMACOLOGICAL TARGET

Symposium

t

ue

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

C

haired

: r.G. s

Chnellmann

3:00 

New methods to identify changes in mitochondrial 

function. 

C. C. Beeson. Med. Univ. of South Carolina.

3:35 

MitoQ and prevention of mitochondrial dysfunction. 

V. 

Darley-Usmar. Univ. of Alabama at Birmingham.

4:10 

Mitochondrial etiology of Alzheimer’s and Parkinson’s 

disease. 

D. C. Wallace. Children’s Hosp. of 

Philadelphia.

4:45 

Drugs that target mitochondrial biogenesis accelerate 

the recovery of cellular and organ function. 

R. G. 

Schnellmann. Med. Univ. of South Carolina.

5:20 Discussion.

407.  BEHAVIORAL PHARMACOLOGY DIVISION: 

THE OPIOID-CANNABINOID CONNECTION: A 

TRANSLATIONAL, BEHAVIORAL PERSPECTIVE

Symposium

t

ue

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109a

C

haired

: m. h

aney

 

anD

 z.D. C

ooper

3:00 

The endogenous cannabinoid system: an emerging 

target to treat opioid and cannabinoid dependence. 

A. 

H. Lichtman. Virginia Commonwealth Univ.

3:30  Pharmacological and neurobiological studies 

investigating opioid and endocannabinioid interactions 

in rodent models of stress-induced analgesia. 

D. P. 

Finn. Univ. of Ireland, Galway.

4:00 

Pharmacological evidence for opioid modulation of the 

reinforcing effects of CB1 receptor agonists in non-

human primates. 

Z. Justinova. NIDA, NIH, Baltimore.

4:30 

Naltrexone alters marijuana’s analgesic and intoxicating 

effects in daily marijuana smokers. 

Z. D. Cooper. 

Columbia Univ. Col. of P&S.

5:00 

The potential clinical efficacy of cannabinoid agonists 

in treating opioid-dependent patients. 

A. Bisaga. New 

York State Psychiat. Inst.

Physiology

APS President’s Symposium Series

From Animals to Human Models of Disease

408.  EATING DISORDERS

Symposium

t

ue

. 3:15 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 210BC

C

haired

: m. B

oGGiano

Translational Physiology

3:15 

Identifying mechanisms that drive compulsive exercise 

and self-starvation in a translational model of anorexia 

nervosa.